Bradley Pharmaceuticals to Report Second Quarter 2007 Financial Results and Schedules Conference Call
31 Julho 2007 - 8:45AM
PR Newswire (US)
FAIRFIELD, N.J., July 31 /PRNewswire-FirstCall/ -- Bradley
Pharmaceuticals, Inc. (NYSE:BDY) announced today that the Company
will release its second quarter 2007 financial results on Thursday,
August 9, 2007, after the close of the financial markets. Daniel
Glassman, President and CEO, will host a conference call on Friday,
August 10, 2007 at 8:30 a.m. Eastern Time to review the results for
the quarter. To participate in the call via telephone, please dial
1-888-573-3046 approximately 10 minutes prior to the start of the
call and enter ID #11333497. A conference call replay will be
available after 1:00 PM ET by calling 1-800-642-1687 and entering
reservation ID #11333497. To access the call live on the Internet,
please visit the Investor Relations section on the Company's
website at http://www.bradpharm.com/. The call will be available on
the web page for 30 days. For more information about Bradley
Pharmaceuticals, please visit: http://www.bradpharm.com/. About
Bradley Pharmaceuticals, Inc. Bradley Pharmaceuticals, Inc. was
founded in 1985 as a specialty pharmaceutical company and markets
to niche physician specialties in the U.S. and international
markets. Bradley's success is based upon its core strengths in
marketing and sales, which enable the company to Commercialize
brands that fill unmet patient and physician needs; Develop new
products through life cycle management; and In-License phase II and
phase III drugs with long-term intellectual property protection
that, upon approval, leverage Bradley's marketing and sales
expertise to increase shareholder value. Bradley Pharmaceuticals is
comprised of Doak Dermatologics, specializing in therapies for
dermatology and podiatry; Kenwood Therapeutics, providing
gastroenterology, OB/GYN, respiratory and other internal medicine
brands; and A. Aarons, which markets authorized generic versions of
Doak and Kenwood therapies. Safe Harbor for Forward-Looking
Statements This release contains "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. Forward-looking statements include statements that address
activities, events or developments that Bradley expects, believes
or anticipates will or may occur in the future. Forward-looking
statements are subject to numerous risks and uncertainties, many of
which are beyond Bradley's control. Actual results may differ
materially from those projected. These risks and uncertainties
include those described from time to time in Bradley's SEC filings,
including its Annual Report on Form 10-K and its most recent
Quarterly Report on Form 10-Q. Except as required by law, Bradley
undertakes no obligation to publicly update any forward-looking
statement in this press release, whether as a result of new
information, future events or otherwise. DATASOURCE: Bradley
Pharmaceuticals, Inc. CONTACT: Cecelia C. Heer, Investor and Public
Relations, of Bradley Pharmaceuticals, Inc., +1-973-882-1505, ext.
252, or Web site: http://www.bradpharm.com/
Copyright
Bradley (NYSE:BDY)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Bradley (NYSE:BDY)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024
Notícias em tempo-real sobre Bradley Pharmaceuticals da New York Stock Exchange bolsa de valores: 0 artigos recentes
Mais Notícias de Bradley Pharmactcl